Navigation Links
Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
Date:12/17/2008

l be presented at an upcoming medical meeting, along with additional efficacy data from the 240 mg/day and lower dose groups. Final selection of the Phase 3 dose will be made following completion of data analyses.

"We are pleased to have reached another development milestone in our prostate cancer program by successfully completing enrollment in our Phase 1-2 clinical trial in castration-resistant prostate cancer patients with limited treatment options," said Lynn Seely, M.D., chief medical officer of Medivation. "We look forward to presenting additional data from this trial and to advancing this program into Phase 3 development in 2009, as we have previously guided."

About Prostate Cancer and MDV3100

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer. An estimated 186,320 new cases are expected to be diagnosed in 2008, and approximately 28,660 men are expected to die this year from the disease. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Overexpression of the androgen receptor is believed to contribute to the progression of castration-resistant prostate cancer. MDV3100 is a novel small-molecule androgen receptor antagonist that inhibits androgen receptor function by blocking nuclear translocation of the androgen receptor and DNA binding.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation entered into a global agreement with Pfizer Inc to de
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
8. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
9. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
10. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
11. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... New York , August 27, 2014 ... United States  Laparoscopes Market Outlook to ... 2020", provides key market data on the United ... millions of US dollars, volume (in units) and average ... (Rigid Tip Video Laparoscopes and Flexible Tip Video Laparoscopes), ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces that a ... Baby Food Eastern Europe 2014 ... Eastern Europe 2014" is a new report by ERC ... Eastern Europe , key segments, features ... report also examines trends which are currently affecting the ...
(Date:8/27/2014)... 2014 Sihuan Pharmaceutical Holdings Group Ltd. ... leading pharmaceutical company with the largest cardio-cerebral vascular ... prescription drug market, today announced the unaudited ... (collectively the "Group") for the six months ended ... HighlightsFor the Six months ended 30 JuneKey Income ...
Breaking Medicine Technology:United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 2United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 3United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 4United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 5Baby Food Eastern Europe 2014 2Baby Food Eastern Europe 2014 3Baby Food Eastern Europe 2014 4Baby Food Eastern Europe 2014 5Baby Food Eastern Europe 2014 6Baby Food Eastern Europe 2014 7Baby Food Eastern Europe 2014 8Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7
... SANTA FE, N.M., March 11, 2011 Qforma, an ... appointments of Elna Hamp to Vice President, Business Development ... our clients, business models continue to evolve with the ... to Qforma," said Al Reicheg, Chief Commercial Officer of ...
... Medical International Limited (NYSE: MR ), a leading ... that it will present at the 14th Annual Credit Suisse ... 25th at the Conrad Hotel in Hong Kong. The attendees ... Ms. May Li, Director of Finance and IR; and Ms. ...
Cached Medicine Technology:Qforma Appoints Two New Executives 2
(Date:8/27/2014)... 2014 (HealthDay News) -- A new genetic discovery about ... the bowel disorder, researchers report. The scientists ... how their genes work, and said these changes can ... the possibility of a simple diagnostic test for Crohn,s, ... develops and suggest possible gene targets for new treatments, ...
(Date:8/27/2014)... August, 27, 2014) An experimental drug designed to help ... first treatment for anemia of inflammation, according to results from ... online today in Blood , the Journal ... is a condition that occurs when red blood cells are ... individual has anemia, the body does not get enough oxygen, ...
(Date:8/27/2014)... tested an advanced statistical model to evaluate the ... as published yesterday in Human Genetics . ... in current analyses. Complex diseases like cancer usually ... factors. When many such combinations are studied, identifying ... combinations among affected individuals becomes difficult. In this ...
(Date:8/27/2014)... 2014 The Global and China Maleic ... the current state of the Maleic Anhydride industry in ... overview of the industry, including definitions, applications and industry ... analysis are provided with a focus on history, developments, ... between the international and Chinese situation is also offered. ...
(Date:8/27/2014)... Sugar Manufacturing in Australia ... in global supply and demand, which have contributed to ... industry derives a large share of its revenue from ... dynamics, with supply and prices being determined by larger ... Australian dollar for the majority of the past five ...
Breaking Medicine News(10 mins):Health News:Scientists Spot Genetic Clues to Crohn's Disease 2Health News:Drug represents first potential treatment for common anemia 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 2Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 3Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 4Health News:Maleic Anhydride Industry & Isoprene Market Global and China Analysis Now Available at ReportsnReports.com 5Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Sugar Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4
... the Staying Sharp session on October 4 at the Embassy ... Part of a highly recognized series, the program will emphasize ... industry; factors that predict future cognitive function; and the importance ... The public can reserve free tickets through the toll-free line: ...
... articulating wall mounted arms that offer a space-saving solution without ... environment. , ... Ferndale, MI (PRWEB) ... the next generation in articulating wall-mounted arms. Offering 270 degrees ...
... Oct. 1 Sysmex America, Inc. and its,subsidiary, ... the,company,s new brand logo, said Kazuya Obe, Executive ... The timing of this brand change,corresponds with the ... and,the company,s 40th anniversary. The new logo marks ...
... with,solutions and recommendations drawing on experience working ... PLYMOUTH MEETING, Pa., Oct. 1 Anticipating,the ... Safety and Quality,Improvement Act of 2005, ECRI ... to improve patient care, will preview its ...
... Researchers at the Farber Institute for Neurosciences ... Psychiatry and Human Behavior at Jefferson Medical College ... $3.7 million grant from The National Eye Institute ... macular degeneration (AMD). Barry W. Rovner, M.D., ...
... Rise of cities, risky behavior in west central Africa between ... 1 (HealthDay News) -- The most pervasive global strain of ... a new study claims. , The research, which is ... that HIV began spreading between 1884 and 1924, around the ...
Cached Medicine News:Health News:Enovate IT Announces Fluid - a New Movement in Wall Arms 2Health News:Sysmex Announces Brand Change 2Health News:ECRI Institute Unveils Comprehensive Patient Safety Organization (PSO) Services 2Health News:ECRI Institute Unveils Comprehensive Patient Safety Organization (PSO) Services 3Health News:Jefferson awarded multi-million dollar grant from National Eye Institute for new clinical trial 2Health News:HIV Outbreak Began Decades Earlier Than Thought 2
TSH EIA Thyroid Function 025-BC-1001...
... The anti-TG test kit is a ... microplate format. It is designed for the ... thyroglobulin (TG) in serum or plasma. The ... 1: Calibrators, controls and patient samples are ...
Free Estriol (E3) RIA Reproductive Hormones 024-IDC-1000...
FSH EIA Reproductive Markers 025-BC-1029 Follicle Stimulating Hormone...
Medicine Products: